CRCT - Cancer Research Center of Toulouse
ResearchResearch Teams14 E. Chatelut: Dose individualisation of anticancer drugs

14 E. Chatelut: Dose individualisation of anticancer drugs

 

Team Research Project

Team 14 (E. Chatelut): to promote and carry out translational and clinical studies in the field of pharmacology to drive dose individualisation of anticancer drugs

The main objective of our team is to promote and carry out translational and clinical studies in the field of pharmacology to drive dose individualisation of anticancer drugs.

This is made possible by increasing our understanding of the sources of interindividual variability in drug disposition and tumor response. Our main projects focus on pharmacokinetics and pharmacogenetics as interindividual variability factors.

More than 99% of anticancer treatments are prescribed according to standard doses (in mg/m² for cytotoxics or in mg for several targeted therapies). However, a number of observations have shown that interindividual pharmacokinetic (PK) variability contributes to differences between patients both in terms of toxicity and antitumor response. The very limited number of examples of individual dosing in everyday practice in oncology is mainly due to the administration schedule of cytotoxics (i.e. intravenous administration every three weeks).  Indeed, these schedules make PK exploration difficult to perform in the first place, as several blood samples are needed in order to determine accurately the area-under-the-curve of drug plasma concentrations versus time (AUC), and secondly the PK results obtained are useless once the administration is over.

Our Unit uses the nonlinear mixed effects approach (commonly known as “population PK”) to improve dose individualisation of anticancer drugs. Our research may be divided into three areas: (i) covariate identification to explain PK variability, (ii) Bayesian approach to determine individual PK parameters from limited blood sampling, and (iii) pharmacokinetic-pharmacodynamic (PK-PD) modeling.

The analytical resources of the lab include Absorption Atomic Spectophotometric, and UPLC-MS-MS systems.

The team is part of PHUC CAPTOR program

 

Keywords

  • Population pharmacokinetics
  • Platinum compounds
  • Tyrosine kinase inhibitors
  • Therapeutic drug monitoring
  • PK-PD relationships

Publications

 

Team members
ALLAL
Ben

    +33 (0)5 31 15 52 10 
Researcher - other
ARELLANO
Cécile

  
University Teacher / Researcher - MCU

Etienne CHATELUT CHATELUT
Etienne

    +33 (0)5 31 15 52 50 
Hospital Practitioner - PU-PH
DELMAS
Caroline

   +33 5 82 74 16 04 
Technician - T

Thierry LAFONT LAFONT
Thierry

   +33 (0)5 31 15 52 03 
Technician - AI
LOCHON
Isabelle

  
Technician - AI

MARSILI
Sabrina

  
Technician - T
MOEUNG
Sotheara


PhD student

PALUDETTO
Marie-Noêlle

  
PhD student
PUISSET
Florent

  
Hospital Practitioner - MCU-PH

Fabienne THOMAS THOMAS
Fabienne

  
Hospital Practitioner - MCU-PH
VACHOUX
Christelle

  
Technician - T

WHITE-KONING
Mélanie

  
University Teacher / Researcher - MCU
 
Events

 Intertwined roles of NER Factors in transcription and DNA repair Impact of their deregulation in Xeroderma Pigmentosum
01/06/2017- Dr Nicolas Lemay - Salle C. Cazaux - 11:00 - 12:00

 Selective Targeting and Delivery of Therapeutics to Cancer Cells and Tumors Based on the Tumor Microenvironment
29/05/2017 - Dr Damien Thevenin - Salle C. Cazaux - 11:00 - 12:00
Tools
ContactContact
MapMap
DirectoryDirectory
Inserm Université Toulouse 3 - Paul Sabatier CNRS